BSE · CONCORD

Concord Drugs Limited

Sector: Healthcare · ISIN: INE858L01010

Historical price visualisation is temporarily undergoing corporate data-licensing maintenance. Full interactive price and chart data will return following our upcoming authorized NSE/BSE data-feed deployment. Derived metrics (valuation ratios, market-cap rank), company financials, shareholding, corporate actions, and mutual-fund holdings remain available.

Market cap rank

#2,962

of 5,088 stocks

▼ 131W

Peak #2,922 · 27 Sep 2026

Concord Drugs Limited, a microcap Healthcare business, carries a steep earnings multiple that prices in strong future growth, is growing revenue rapidly, and has a subdued return on equity. Ownership as of Jun 2026.

Market Cap

98.19 Cr

P/E Ratio

78.45

P/B Ratio

2.02

ROE

2.17%

ROCE

5.92%

Dividend Yield

—

52W High

—

52W Low

—

Quarterly financials

Metric	Q1 2026-27	Q4 2025-26	Q3 2025-26	Q2 2025-26
Revenue	20.94 Cr	37.89 Cr	16.97 Cr	10.28 Cr
Net Profit	1.11 Cr	52.80 L	21.70 L	19.24 L
EPS	0.85	0.47	0.16	0.31
Operating Profit	1.94 Cr	1.14 Cr	63.59 L	75.94 L

Figures in Cr (crore) unless noted. Source: official company financial disclosures.

Shareholding pattern

Promoter

45.08%

Public

54.92%

PUBLIC BREAKDOWN

Individuals

54.29%

As of 30 Jun 2026. FII, DII, MF & Individuals are sub-categories of Public.

Mutual fund holdings

Mutual fund holdings data for this stock hasn't been ingested yet — check back soon.

Recent corporate actions

No corporate actions on record for this stock.

Need this data in your app?

Full price history, technical indicators, and every field above via one REST API call.

View API docs